Can-Fite BioPharma Ltd.
New York Stock Exchange ArcaTotal Valuation
Can-Fite BioPharma Ltd. carries a market capitalization of 2.92M, placing it among publicly traded companies globally. Its enterprise value stands at 11.06M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.92M |
| Enterprise Value | 11.06M |
Share Statistics
Can-Fite BioPharma Ltd. currently has 453,279.00 shares outstanding.
| Shares Outstanding | 453,279.00 |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 11.64, and the price-to-book ratio stands at 3.19.
| PE Ratio | N/A |
| PS Ratio | 11.64 |
| PB Ratio | 3.19 |
| P/TBV Ratio | 3.19 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
| EV / Sales | 14.89 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Can-Fite BioPharma Ltd. maintains a current ratio of 4.90, meaning it holds 4.9x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 4.90 |
| Quick Ratio | 4.42 |
| Debt / Equity | 0.64 |
| Debt / EBITDA | 0.00 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -142.49 |
| Return on Assets (ROA) | -79.22 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Can-Fite BioPharma Ltd.'s stock has declined approximately -82.84615% over the past 52 weeks. The 50-day moving average sits at 3.29, while the 200-day moving average is 3.90.
| Beta (5Y) | N/A |
| 52-Week Price Change | -82.84615% |
| 50-Day Moving Average | 3.29 |
| 200-Day Moving Average | 3.90 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Can-Fite BioPharma Ltd. generated 743,000.00 in revenue and converted that into -7.63M in net income, yielding earnings per share of -38.85. EBITDA reached -8.19M, while operating income came in at -8.19M.
| Revenue | 743,000.00 |
| Gross Profit | N/A |
| Operating Income | -8.19M |
| Pretax Income | -7.63M |
| Net Income | -7.63M |
| EBITDA | -8.19M |
| EBIT | -8.19M |
| Earnings Per Share (EPS) | -38.85 |
Balance Sheet
Can-Fite BioPharma Ltd. holds 8.92M in cash and equivalents against 40,000.00 in total debt, resulting in a net debt position of -4.28M. Total book value stands at 6.24M, with working capital of 7.89M providing operational flexibility.
| Cash & Cash Equivalents | 8.92M |
| Total Debt | 40,000.00 |
| Net Debt | -4.28M |
| Equity (Book Value) | 6.24M |
| Book Value Per Share | 13.77 |
| Working Capital | 7.89M |
Margins
Can-Fite BioPharma Ltd. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -1,102.96 and net profit margin of -1,027.46 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -1,102.96 |
| Pretax Margin | -1,027.46 |
| Profit Margin | -1,027.46 |
| EBITDA Margin | -1,102.96 |
Stock Splits
Can-Fite BioPharma Ltd.'s most recent stock split took place on January 5, 2026 with a 20:1 split ratio.
| Last Split Date | 1/5/2026 |
| Split Ratio | 20:1 |
Scores
Can-Fite BioPharma Ltd. posts an Altman Z-Score of -20.70, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -20.70 |